OBI Pharma (4174) — Cash Flow-to-Debt Ratio
OBI Pharma (4174) has a Cash Flow-to-Debt Ratio of -0.59x as of June 2026, meaning its operating cash flow of NT$-290.40 Million could theoretically repay -1% of its total liabilities (NT$495.56 Million) in one year. See OBI Pharma (4174) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
OBI Pharma Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for OBI Pharma across 15 annual periods. For the full cash flow conversion analysis, see OBI Pharma cash flow conversion.
Annual Cash Flow-to-Debt Ratio for OBI Pharma (2011–2025)
Year-by-year debt coverage analysis for OBI Pharma. Check OBI Pharma earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.90x | NT$-2.02 Billion | NT$696.13 Million | ▼ -31.9% |
| 2024 | -2.20x | NT$-1.83 Billion | NT$833.38 Million | ▲ +13.4% |
| 2023 | -2.54x | NT$-1.65 Billion | NT$650.45 Million | ▲ +21.9% |
| 2022 | -3.26x | NT$-1.62 Billion | NT$497.57 Million | ▼ -88.4% |
| 2021 | -1.73x | NT$-1.06 Billion | NT$615.95 Million | ▲ +46.1% |
| 2020 | -3.21x | NT$-1.61 Billion | NT$502.09 Million | ▼ -40.6% |
| 2019 | -2.28x | NT$-1.05 Billion | NT$459.14 Million | ▲ +37.7% |
| 2018 | -3.66x | NT$-864.31 Million | NT$236.03 Million | ▲ +57.1% |
| 2017 | -8.54x | NT$-1.11 Billion | NT$129.66 Million | ▼ -70.0% |
| 2016 | -5.02x | NT$-840.10 Million | NT$167.32 Million | ▼ -71.3% |
| 2015 | -2.93x | NT$-372.20 Million | NT$127.00 Million | ▲ +72.1% |
| 2014 | -10.49x | NT$-464.22 Million | NT$44.24 Million | ▼ -317.7% |
| 2013 | -2.51x | NT$-104.16 Million | NT$41.46 Million | ▲ +5.2% |
| 2012 | -2.65x | NT$-117.64 Million | NT$44.40 Million | ▲ +92.6% |
| 2011 | -35.61x | NT$-508.22 Million | NT$14.27 Million | — |